Objective response rate of 54.8% seen with Daiichi Sankyo and Merck’s ifinatamab deruxtecan at 12 mg/kg dose in pretreated patients
PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration
H.coagulans is, unlike other general lactobacillus, characterized by spore formation, giving it resistance to acid and heat
The new bioeconomy policy rolled out by the Modi government is set to place India as a global leader in the years to come
PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration
The JV will establish a state-of-the-art manufacturing facility to manufacture fermented animal free protein to cater to the global markets
Novartis has option to acquire two future development-ready programs to augment its renal portfolio, a strategic area of focus for the company
The drugmaker's net profit slipped 26 per cent on-year to Rs 143.8 crore
Revolutionary technology will further boost OneSource’s scientific services offerings
Boehringer Ingelheim aims to develop this program as a potential key centerpiece component for its immuno-oncology portfolio
Subscribe To Our Newsletter & Stay Updated
